t
Coiled Therapeutics plc posted its Notice of Annual General Meeting to Shareholders on 27 May 2026. The Annual General Meeting is scheduled for 10:00 am on 24 June 2026, at the offices of Reynolds Porter Chamberlain LLP in London.
| Date | 27 May 2026 |
| Time | 07:00:06 |
| Category | AGMs and other meetings |
| ID | 7608F |
27 May 2026
Coiled Therapeutics plc
("Coiled Therapeutics" or the "Company")
Notice of Annual General Meeting
Coiled Therapeutics (AIM:COIL, OTCQB:COTXF), the clinical-stage oncology company developing precision medicines for hard-to-treat cancers, has today posted its Notice of Annual General Meeting to Shareholders. The Annual General Meeting is scheduled to take place at the offices of Reynolds Porter Chamberlain LLP, Tower Bridge House, St Katharine's Way, London E1W 1AA at 10.00 am on 24 June 2026.
The Notice of Annual General Meeting and Forms of Proxy can be downloaded from the Company's corporate website at: https://coiledplc.com/investors/circulars-meetings
|
Coiled Therapeutics plc Sotirios Stergiopoulos (Chairman) Sridhar Vempati (CEO)
|
Via Burson Buchanan |
|
SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker) David Hignell / Adam Cowl / Devik Mehta (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)
|
+44 (0)20 3470 0470
|
|
Shard Capital Partners LLP (Joint Broker) Damon Heath
CPS Capital Group Pty Ltd (Joint Broker) Jason Peterson / David Valentino
|
+44 (0)20 4530 6926
+61 (0)8 9223 2222 |
|
Burson Buchanan (Public Relations) Henry Harrison Topham / Jamie Hooper / Toto Berger
|
+44 (0)20 7466 5000
|
|
Harbor Access (US Investor Relations) Matt Kelly / Jonathan Paterson |
+1 475 477 9404 |
About Coiled Therapeutics plc
Coiled Therapeutics (AIM: COIL, OTCQB: COTXF) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications. Coiled Therapeutics is supported by a leadership team with a proven track record in drug development and strategic backing from A2A Pharmaceuticals.
About AO-252
AO-252 is a first-in-class, orally administered, brain-penetrant small molecule inhibitor of Transforming Acidic Coiled-Coil containing protein 3 (TACC3). TACC3 is a validated oncology target that is frequently overexpressed in many aggressive, hard-to-treat solid tumours but is dispensable in normal adult cells, providing a wide therapeutic window.
By selectively disrupting cancer-critical protein-protein interactions at the TACC3 C-terminal domain, AO-252 induces mitotic and replication stress, impairs DNA damage repair, and triggers cancer cell death. Notably, AO-252 has demonstrated the ability to cross the blood-brain barrier, addressing a significant unmet medical need for the treatment of brain metastases.
The asset is currently in an ongoing Phase I open-label dose-escalation study and early clinical signals have shown encouraging anti-tumour activity and a benign safety profile, with the Company planning to initiate dose expansion cohorts in lead indications, including prostate and ovarian cancer, during 2026.
For more information, please visit: www.coiledplc.com